Immune dysregulation in long COVID patients uncovered in new study

Sstudy reveals significant immune changes in long COVID patients, including altered T cell responses and systemic inflammation, using advanced ‘omics’ and serological assays.

Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data

Rise and shine, everyone, another busy day is on the way. We can tell because the official mascots are racing about the Pharmalot grounds and

November 16, 2023

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference | Psychedelic Invest

NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment

September 4, 2024

Updated: Amgen spotlights new efficacy, safety data of mid-phase tarlatamab trial in hard-to-treat cancer: #ESMO23

MADRID — Amgen’s Phase II trial of its bispecific T cell engager tarlatamab showed a response rate of 40% of patients with small cell lung

October 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.